VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XLO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XLOXilio Therapeutics, Inc.
$7.54$50M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
XLO logo

Xilio Therapeutics, Inc.

XLO
NASDAQ · Oncology Biotech
$7.54
At close - Nov 17, 4:00 PM EST - USD
Market Cap$50M
P/E-12.9x
52W High$11.30
Volume6.15K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Lumpy Collaboration Revenue Fails to Offset Persistent Cash Burn

Xilio Therapeutics' reported revenue has swung widely, from $2.9M in 2025Q1 to $19.1M in 2025Q3 and $18.7M in 2026Q2, suggesting milestone or collaboration recognition rather than a steady commercial base.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

XLO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-149% Peers

P/E is 149% below peer median

03

Market leadership

RS 41 · Lag

Laggard (Underperforming 59% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 10

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
XLO-19.79%
S&P 500 (^GSPC)+7.21%
1-Year Return
XLO-25.64%
S&P 500 (^GSPC)+10.03%
3-Year Return
XLO-56.91%
S&P 500 (^GSPC)+64.78%
5-Year Return
XLO-97.73%
S&P 500 (^GSPC)+58.79%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-13.1x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-13.1x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$96.84+1184.4%
Base (Fair)$116.85+1174.3%
Bull$142.10+1784.6%
$96.84 Bear$116.85 Base$142.10 Bull
Current Market Price: $7.54
Trades at a 93.5% discount to Base DCF ($116.85)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$44M+589.9% YoY
Net income FY25
-$35M+39.8% YoY
Free cash flow FY25
-$6M+70.1% YoY
Operating margin FY25
-95.9%+859.0 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-1422.7%
ROE (TTM)-18.5%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate5/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 10, 2026
-$0.30+67.9%
vs -$0.94
$10M+102.8%
vs $5M
Q3 2026
Aug 13, 2026
-$0.33+44.1%
vs -$0.59
$19M+46.9%
vs $13M
Q2 2026
May 12, 2026
-$0.58+12.1%
vs -$0.66
$13M+48.5%
vs $9M
Q2 2026
Mar 23, 2026
-$0.85+49.4%
vs -$1.68
$14M+25.6%
vs $11M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 10, 2026
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 Advancing XTX602, a dual-masked CLDN18.2-targeting multi-specific TCE with co-stimulation, and XTX701, a masked PSMAxSTEAP1-targeting multi-specific TCE with co-stimulation, toward planned IND applications in the fourth quarter of 2027 WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2026.

GlobeNewsWire·Nov 3, 2026
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET.

GlobeNewsWire·Oct 26, 2026
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors

GlobeNewsWire·Oct 2, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics' Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company's newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

Filtered for Xilio Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark XLO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Xilio Therapeutics, Inc. (XLO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
XLO logoXLOXilio Therapeutics, Inc.Current
$7.54$49.58M-12.92589.88%-20.89%-18.51%—
NKTX logoNKTXNkarta, Inc.
$1.25$89.43M-0.72——-48.58%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
RCUS logoRCUSArcus Biosciences, Inc.
$16.39$2.06B-4.69-4.26%-445%-90.04%—
AGEN logoAGENAgenus Inc.
$6.21$258.6M18.4110.37%20.98%——
CLDX logoCLDXCelldex Therapeutics, Inc.
$28.04$1.87B-7.12-78.63%-275986.61%-52.67%—

Compare XLO vs Peers

Xilio Therapeutics, Inc. (XLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NKTX

Most directly comparable listed peer for XLO.

Scale Benchmark

vs MRK

Larger-name benchmark to compare XLO against a more recognizable public peer.

Peer Set

Compare Top 5

vs NKTX, IMVT, RCUS, AGEN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

XLO SEC Filings & Documents

Xilio Therapeutics, Inc. (XLO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 10, 2026·SEC

Material company update

Aug 12, 2026·SEC

Material company update

Jun 12, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Apr 1, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 10, 2026·SEC

FY 2026

Aug 12, 2026·SEC

FY 2026

May 12, 2026·SEC

Get notified when XLO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

XLO Frequently Asked Questions

Xilio Therapeutics, Inc. (XLO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Xilio Therapeutics, Inc.'s revenue?

Xilio Therapeutics, Inc. (XLO) reported $55.0M in revenue over the trailing twelve months. Revenue was $43.8M in fiscal year 2025.

How fast is Xilio Therapeutics, Inc. growing?

Xilio Therapeutics, Inc. (XLO) grew revenue by 73.0% over the trailing twelve months, compared with the twelve months before.

Is XLO profitable?

No. Xilio Therapeutics, Inc. (XLO) reported a net loss of $11.5M over the trailing twelve months.

Dividend & Returns
What is XLO's return on equity?

Xilio Therapeutics, Inc. (XLO) had a return on equity (ROE) of -18.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Xilio Therapeutics, Inc.'s free cash flow?

Xilio Therapeutics, Inc. (XLO) had negative free cash flow of $57.6M over the trailing twelve months.

What if you invested $1,000 in XLO back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →